CRXL - Sector: Healthcare --- Industry: Biotechnology & Drugs

[setravis]

News......A Buy Signal......
I am already in this stock, have been for 2 years. I took half the profits
off the table last week.

http://stockcharts.com/def/servlet/SC.web?c=crxl


LEIDEN, Netherlands, Jun 10, 2005 (PRIMEZONE via COMTEX) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (CRXL) today announces the discovery of a monoclonal antibody for protection against West Nile virus. Study results have demonstrated that the fully human monoclonal antibody, derived from patients who survived West Nile infection, effectively neutralized the virus in cell culture and fully protected mice from an otherwise lethal infection.



AMSTERDAM, June 10 (Reuters) - Dutch biotechnology firm Crucell ((CRCL.AS))(CRXL,Trade) said on Friday it had discovered a human antibody for protection against West Nile virus that has proven effective in animal studies.

"Study results have demonstrated that the fully human monoclonal antibody, derived from patients who survived West Nile infection, effectively neutralized the virus in cell culture and fully protected mice from an otherwise lethal infection," Crucell said in a statement.

Crucell shares gained on the news, rising 4.4 percent to 17 euros, their highest level since October 2000, the month of their initial public offering.

The company, which has never reported a profit, has reported significant progress in developing vaccines against Ebola, the West Nile Virus and SARS.

Crucell's West Nile virus vaccine development programme is due to enter clinical trials at the end of this year.

Since appearing in New York in 1999, the West Nile virus has spread by mosquitos throughout the United States. In 2004, there were 2,470 recorded cases of the disease and 88 fatalities caused by a form of encephalitis, or inflammation of the brain.

[setravis]

Not anyone was ever interested in this stock
It sure has an awesome chart........

[setravis]

All the news articles:

http://finance.yahoo.com/q/h?s=CRXL

[Lucas Scott]

hey Travis, I'm long CRXL as well. Beautiful long term chart. I'm a follower of Trudy the Monkey on this one.

"Trudy is a very patient monkey when it comes to CRXL. Someone asked her the target, and she said "2010!" When they asked further, she said "that's a year or a dollar amount, depending which comes first." 

[setravis]

This is awesome......

• Crucell to Release Third Quarter Results on Monday, October 17
PrimeZone Media Network (Mon, Oct 3) 

Technicals
Last Price Quote is:
8.61%above 13-day EMA
19.68%above 50-day EMA
RS Rating: 90 

Fundamentals
Earnings Expected on Oct 17

Key Data:
Market Cap (M): $988.57 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 10/17/2005

[REALDEALS21]

Up big on HUGE volume ! Crushed the 52 week high !

[setravis]

Awesome .....Looks better all the time.....

[setravis]

Press Release Source: Crucell N.V.


Crucell N.V.: Merck and Co., Inc. Exercises Option on PER.C6 License for Adenovirus-based Vaccine Against Hepatitis C
Monday October 10, 2:17 am ET


LEIDEN, Netherlands, Oct. 10, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (NasdaqNM:CRXL - News) announced today that Merck & Co., Inc. (NYSE:MRK - News) has exercised its option to use Crucell's PER.C6(r) production technology to develop an adenovirus-based vaccine against hepatitis C (HCV). Crucell will receive a US$ 1 million (0.8 million) exercise fee with the prospect of annual fees and milestone payments, plus royalties on net sales.

 
Merck already uses PER.C6(r) technology for its adenovirus-based HIV vaccine, currently in proof-of-concept Phase II trials.

``It is extremely satisfying to see that PER.C6(r) can play a role in the fight against such a widespread and serious infection as hepatitis C,'' said Dr. Ronald Brus, Crucell's Chief Executive Officer. ``There is no question that the world needs a vaccine against HCV.''

Under the terms of the agreement, Crucell has retained 'co-exclusive' rights which provide the Company with the option of developing or co-developing its own HCV vaccine. ``Crucell believes that, as with diseases like HIV/AIDS, malaria and TB, adenovirus-based vaccines may prove to be a fruitful approach for HCV because of their ability to induce both cellular and humoral immunity and the scalability that our PER.C6(r) technology can provide,'' explained the Company's Chief Scientific Officer Dr. Jaap Goudsmit.

About HCV

Hepatitis C is a disease of the liver caused by the hepatitis C virus (HCV). HCV is spread primarily by direct contact with human blood, with intravenous drug use employing contaminated needles being among the causes of transmission. The World Health Organization (WHO) estimates that approximately 200 million people, 3% of the world's population, are infected with HCV, with 3-4 million people newly infected each year. About 85% of infected people become chronically infected and 70% develop chronic hepatitis, putting them at risk of developing cirrhosis of the liver or liver cancer. WHO estimates that hepatitis C is an epidemic disease in 131 countries around the world, and is responsible for 50-76% of all liver cancer cases and two-thirds of all liver transplants in the developed world. No vaccine currently exists for the prevention of HCV infection.

About Crucell

Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria, West Nile virus and rabies. The company's development programs include collaborations with: Sanofi Pasteur for influenza vaccines; the U.S. National Institutes of Health for Ebola and malaria vaccines; and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its PER.C6(r) production technology. The company also licenses its PER.C6(r) technology to the biopharmaceutical industry. Licensees and partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information, please visit http://www.crucell.com.

Crucell's Licensing Program Disclosure Policy

Crucell believes it has a duty to inform (potential) investors and other stakeholders about every licensing agreement it reaches with third parties -- regardless of the significance of current or future revenue or royalties generated by the agreement. Crucell fulfils this duty by issuing a press release that invariably consists of the name of the contract party, the nature of the license and an indication of the relevant technology or therapeutic area. This ensures that every potential investor or interested party can be fully up-to-date with all licensing agreements made by Crucell with third parties. An overview of all Crucell's licensees and partners can be found on the Company's website, including an overview of each relevant product's phase of development.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 14, 2005, and the section entitled ``Risk Factors''. The company prepares its financial statements under generally accepted accounting principles in the United States (U.S. GAAP).

Click here for a PDF version of this press release:

http://hugin.info/132631/R/1014723/158534.pdf



Contact:
          Crucell N.V.
          Harry Suykerbuyk
          Director Investor Relations and Corporate Communications
          Tel. +31-(0)71-524 8718
          [email protected]

          For Crucell in the U.S.:
          Redington, Inc.
          Thomas Redington
          Tel. (212) 926-1733
          [email protected]


--------------------------------------------------------------------------------
Source: Crucell N.V.

[setravis]

UPDATE 1-Crucell leaps after Merck deal on hepatitis vaccine
Mon Oct 10, 2005 05:03 AM ET
By Karl Emerick Hanuska and Lucas van Grinsven
AMSTERDAM, Oct 10 (Reuters) - Shares in Crucell (CRCL.AS: Quote, Profile, Research) hit a high for the year on Monday after news that pharmaceuticals giant Merck & Co. (MRK.N: Quote, Profile, Research) will use the Dutch biotech firm's technology to develop a vaccine against hepatitis C.

Traders and analysts said the announcement by Crucell (CRXL.O: Quote, Profile, Research) -- whose PER.C6 gene technology aims at using human cells as a platform to produce drugs and vaccines -- gave further evidence that the firm was on its way to turning a profit.

Merck is already using PER.C6 for its adenovirus-based HIV vaccine, which is currently in proof-of-concept Phase II or mid-stage trials.

"This deal with Merck is another milestone in the development of Crucell," said one Dutch trader.

"News like this continues to come out of the company that points to good demand for PER.C6 and to money coming in and to Crucell turning a profit."

Under the the terms of the deal with Merck, which is exercising an option to use the PER.C6 technology, Crucell will receive a $1 million exercise fee with the prospect of annual fees and milestone payments, plus royalties on net sales.

Merck intends to use PER.C6 to develop an adenovirus-based vaccine against hepatitis C -- a liver disease caused by a virus that infects around 200 million people.

Adenoviruses infect tissue linings of the respiratory tract, eyes, intestines and urinary tract.

They have significant potential for the development of vaccines and gene therapy because they can be genetically altered to stimulate an immune response in humans.

No vaccine exists to prevent hepatitis C infection but there are treatments available that are effective in about half of all cases, according to the U.S. Department of Health.

Shares in Crucell, which has reported significant progress in developing vaccines against Ebola, the West Nile Virus and SARS, were up 6.9 percent at 24.70 euros by 0853 GMT, after touching 25.40 euros in early trade.

The shares are up more than 130 percent since the start of the year.

While Crucell has yet to turn a profit, licensing deals and service fees are providing funding until final approval of its first products, expected within five years.

Crucell was floated in 2000 and ended its oncology programme in 2003. It then redirected the focus of its antibody discovery group to infectious diseases, a decision that initially scared off some investors but which now seems to be paying off.


© Reuters 2005. All Rights Reserved.

[setravis]

Has been a steady mover.......

[setravis]

She dips ..and she rumbles....she dips ...and she rumbles ! 
Back above the 50-dma.......

[Richard]

She dips ..and she rumbles....she dips ...and she rumbles ! 
Back above the 50-dma.......

Mmmmm, yes...I like this one. (applause)

Throws up these pennants on the weekly charts...history repeats itself maybe one more time? what do you think 35-ish?? Looks possible:

[Lucas Scott]

history repeats itself maybe one more time? what do you think 35-ish??

I have a longer time horizon with my CRXL investment, but yeah I think $35 based on that chart you posted is reasonable. I first bought CRXL at $3.50 back in August 2003 but sold it at $3.97. Wish I was still holding those shares!! Then rode it from $9.50 to $22.50 and sold. Currently in at $22 and holding.

Here are some words of wisdom from Trudy the Monkey, who's a regular on the Yahoo message board:

> Do you have a target for CRXl for the end of the year of
> eighteen months or someting? Do you think it is stil
> capable of major movement, or is the big move over?

Trudy is a very patient monkey when it comes to CRXL. Someone asked
her the target, and she said "2010!" When they asked further, she
said "that's a year or a dollar amount, depending which comes first."

So as an investment strategy, Trudy is accumulating more CRXL, and
holding quite long term.

Really, it is dependent on two orthogonal factors:
(1) the reality of their business success
(2) market perception

Trudy has almost complete confidence in the success of their
business, in fact she thinks they are already well on the way to
revolutionizing the $8 billion vaccine market. The Sanofi Pasteur
deal is certainly their most solid foundation. But they have many
other things going on.

But perception is 9/10ths of the law with stock markets: the share
price could do anything based purely on market mood swings,
publicity, manipulation, etc. Stock markets are run by humans, who
suffer from a missing 24th chromosome pair. Stocks aren't always
priced as they should be.

[setravis]

Press Release Source: Crucell N.V.


Crucell Announces PER.C6 Licensing Agreement with Tibotec
Wednesday November 23, 2:06 am ET


LEIDEN, Netherlands, Nov. 23, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (NasdaqNM:CRXL - News) announced today that it has signed a PER.C6(r) license agreement with Ireland-based Tibotec Pharmaceuticals Ltd. The non-exclusive agreement allows Tibotec to use the PER.C6(r) cell line for research in the field of virology.

Under the terms of the agreement, Tibotec will pay a research license fee, annual maintenance fees and milestone payments. Further financial details were not disclosed.

About Crucell

Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria, West Nile virus and rabies. The company's development programs include collaborations with: sanofi pasteur for influenza vaccines; the U.S. National Institutes of Health for Ebola and malaria vaccines; and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its PER.C6(r) production technology. The company also licenses its PER.C6(r) technology to the biopharmaceutical industry. Licensees and partners include DSM Biologics, GSK, Centocor and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information, please visit http://www.crucell.com.

Crucell's Licensing Program Disclosure Policy

Crucell believes it has a duty to inform (potential) investors and other stakeholders about every licensing agreement it reaches with third parties -- regardless of the significance of current or future revenue or royalties generated by the agreement. Crucell fulfils this duty by issuing a press release that invariably consists of the name of the contract party, the nature of the license and an indication of the relevant technology or therapeutic area. This ensures that every potential investor or interested party can be fully up-to-date with all licensing agreements made by Crucell with third parties. An overview of all Crucell's licensees and partners can be found on the Company's website, including an overview of each relevant product's phase of development.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 14, 2005, and the section entitled ``Risk Factors''. The company prepares its financial statements under generally accepted accounting principles in the United States (U.S. GAAP).

http://hugin.info/132631/R/1022503/161727.pdf



Contact:
          Crucell N.V.
          Harry Suykerbuyk, Director Investor Relations and
          Corporate Communications
          Tel. +31 (0)71 524 8718
          [email protected]

          For Crucell in the U.S.:
          Redington, Inc.
          Thomas Redington
          Tel. (212) 926-1733
          [email protected]


--------------------------------------------------------------------------------
Source: Crucell N.V.

[setravis]

Press Release Source: NASDAQ


Semi-Annual Changes to the NASDAQ Biotechnology Index
Friday November 11, 6:32 pm ET


NEW YORK, Nov. 11 /PRNewswire-FirstCall/ -- The Nasdaq Stock Market, Inc. ("NASDAQ") (Nasdaq: NDAQ - News) announced today the results of the semi-annual re- ranking of the NASDAQ Biotechnology Index® (Nasdaq: NBI - News), which will become effective with the market open on Monday, November 21, 2005.


The re-ranking will result in 17 securities being added to the Index. All securities are classified according to the FTSE Global Classification System(TM) as biotechnology or pharmaceutical. The securities that meet the classification criteria then must meet other Index eligibility criteria including listing on the NASDAQ National Market® and meeting minimum requirements for market value, average daily share volume and seasoning as a public company. The Index is ranked on a semi-annual basis in May and November. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit http://www.nasdaq.com.

As a result of the re-ranking, AEterna Zentaris, Inc. (Nasdaq: AEZS - News), Corgentech Inc. (Nasdaq: CGTK - News), Ciphergen Biosystems, Inc. (Nasdaq: CIPH - News), GTx, Inc. (Nasdaq: GTXI - News), La Jolla Pharmaceutical Company (Nasdaq: LJPC - News), Novavax, Inc. (Nasdaq: NVAX - News) and PRAECIS PHARMACEUTICALS INCORPORATED (Nasdaq: PRCSD - News) will be removed from the Index.

The NASDAQ Biotechnology Index is the basis for the iShares Nasdaq Biotechnology Index(SM) Fund (Amex: IBB - News), which seeks investment results that generally correspond to the price and yield performance of the NASDAQ Biotechnology Index before fees and expenses. In addition, options based on the NASDAQ Biotechnology Index and the iShares Nasdaq Biotechnology Index Fund trade on various exchanges.

NASDAQ® is the largest electronic screen-based equity securities market in the United States. With approximately 3,200 companies, it lists more companies and, on average, trades more shares per day than any other U.S. market. It is home to category-defining companies that are leaders across all areas of business including technology, retail, communications, financial services, transportation, media and biotechnology. For more information about NASDAQ, visit the NASDAQ Web site at http://www.nasdaq.com or the NASDAQ Newsroom at http://www.nasdaq.com/newsroom/.

The FTSE Global Classification System is compiled by FTSE International Limited. Beginning with the May 2006 re-ranking, NASDAQ will be using The Industry Classification Benchmark.

The Industry Classification Benchmark ("ICB") is jointly owned by FTSE International Limited ("FTSE") and Dow Jones & Company, Inc.

FTSE(TM) is a trademark of the London Stock Exchange Plc and The Financial Times Limited and is used by FTSE International Limited under license.

"Dow Jones" and "DJ" are trademarks of Dow Jones & Company Inc.

iShares are distributed by SEI Investments Distribution Co. Barclays Global Fund Advisors serves as an advisor to iShares and is a subsidiary of Barclays Global Investors, N.A., neither of which is affiliated with SEI. For a prospectus, call 1-800-iSHARES (1-800-474-2737).


    IShares are not FDIC Insured.
    Have No Bank Guarantee.
    May Lose Value.

    Company Briefs

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News) is a biotechnology company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi.

Anadys Pharamceuticals, Inc. (Nasdaq: ANDS - News) provides biopharmaceuticals. The company discovers, develops, and commercializes small molecule, anti- infective medicines for the treatment of HCV and bacterial infections.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX - News) a biopharmaceutical company, discovers and designs novel small molecule pharmaceuticals using structure- based drug design. The company's products are used for the treatment of immunological, viral, and cardiovascular diseases and disorders.

Crucell N.V. (Nasdaq: CRXL - News) licenses technology to pharmaceutical and biotechnology companies. Crucell develops treatments for cancer, inflammatory diseases, and influenza.

CoTherix, Inc. (Nasdaq: CTRX - News) is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and chronic diseases.

DURECT Corporation (Nasdaq: DRRX - News) develops and commercializes pharmaceutical systems for the treatment of chronic diseases.

Gen-Probe Incorporated (Nasdaq: GPRO - News) develops, manufactures, and commercializes diagnostic products based on its generic probe technologies. The company's products are used for the clinical diagnosis of human diseases and for screening donated human blood.

Hi-Tech Pharmacal Co., Inc. (Nasdaq: HITK - News) manufactures prescription and over-the-counter generic and branded pharmaceuticals in liquid and semi-solid dosage forms.

Kosan Biosciences Incorporated (Nasdaq: KOSN - News) is a biotechnology company that develops drugs from molecules called polyketides.

Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA - News) is a biotechnology company specializing in sequencing and engineering of complex sugars for the development of novel drugs, and discovery of new biological processes.

Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK - News) researches, develops and manufactures nasally administered pharmaceuticals.

Panacos Pharmaceuticals, Inc. (Nasdaq: PANC - News) is developing the next generation of anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases.

Sirna Therapeutics, Inc. (Nasdaq: RNAI - News) is a biotechnology company utilizing its expertise in nucleic acid technology to develop and commercialize products that target human diseases.

Renovis, Inc. (Nasdaq: RNVS - News) is a biopharmaceutical company developing drugs to treat neurological diseases and disorders.

StemCells, Inc. (Nasdaq: STEM - News) is a biotechnology company. The company discovers, develops, and commercializes stem cell-based therapies to treat diseases of the central nervous system, liver, and the pancreas.

ViaCell, Inc. (Nasdaq: VIAC - News) is a biotechnology company focused on enabling the widespread use of human cells as medicine. In addition to its therapeutic focus, the company offers expecting families the opportunity to preserve umbilical cord blood for potential future medical use.

ViroPharma Incorporated (Nasdaq: VPHM - News) is a pharmaceutical company committed to the development and commercialization of medicines for use by gastroenterologists, hepatologists, and in transplant and hospital settings.




--------------------------------------------------------------------------------
Source: NASDAQ